Key result
Trandolapril reduces mortality and extends life expectancy in post-MI patients with LV dysfunction.
Why the study?
Trandolapril has been developed and studied for its effects on blood pressure, left ventricular hypertrophy, and mortality in patients with hypertension and left ventricular dysfunction after myocardial infarction.
Does trandolapril improve outcomes in patients with mild-to-moderate hypertension and left ventricular dysfunction after myocardial infarction?
Population
Patients with mild-to-moderate hypertension and patients with left ventricular dysfunction after myocardial infarction
Design
Review of pharmacological and clinical studies including the TRACE trial
Authors
Loading...
Supports ACEI benefit post-MI with LV dysfunction; leaves open effects in comorbid mild hypertension.
Does trandolapril improve outcomes in patients with mild-to-moderate hypertension and left ventricular dysfunction after myocardial infarction?
Trandolapril is an effective ACE inhibitor that provides significant blood pressure reduction in hypertensive patients and improves survival in patients with left ventricular dysfunction post-myocardial infarction.
Coca et al. (2003) conducted a review in Left ventricular dysfunction after myocardial infarction and hypertension. Trandolapril was evaluated on Mortality and life expectancy. Trandolapril treatment reduced mortality and increased life expectancy in patients with left ventricular dysfunction after myocardial infarction in the TRACE trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: